Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Cryo-Cell International's Equity-to-Asset or its related term are showing as below:
CCEL'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.97 Med: -0.18 Max: 0.08
Current: -0.29
During the past 13 years, the highest Equity to Asset Ratio of Cryo-Cell International was 0.08. The lowest was -0.97. And the median was -0.18.
CCEL's Equity-to-Asset is ranked worse than 92.99% of 685
companies
in the Healthcare Providers & Services industry
Industry Median: 0.48
vs CCEL: -0.29
Cryo-Cell International (AMEX:CCEL) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Cryo-Cell International Equity-to-Asset Related Terms
Cryo-Cell International Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CCEL vs EHSI, PIII, CCM: Equity-to-Asset Comparison
For the Medical Care Facilities subindustry, Cryo-Cell International's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryo-Cell International Equity-to-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Cryo-Cell International's Equity-to-Asset falls into.
Cryo-Cell International Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Cryo-Cell International's Equity to Asset Ratio for the fiscal year that ended in Nov. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryo-Cell International (CCEL) has a Equity-to-Asset of -0.29 as of May. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cryo-Cell International and its competitors. According to the industry distribution chart, Cryo-Cell International ranks #637 out of 685 companies in the Healthcare Providers & Services industry, placing it in the top 93%.
Is Cryo-Cell International's Equity-to-Asset too high?
Cryo-Cell International's current Equity-to-Asset is -0.29. Based on the distribution chart, Cryo-Cell International ranks #637 out of 685 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Cryo-Cell International has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cryo-Cell International's Equity-to-Asset compare to EHSI and PIII?
According to the Healthcare Providers & Services industry distribution chart, Cryo-Cell International ranks #637 out of 685 companies for Equity-to-Asset. This places Cryo-Cell International in the lower half of its industry. The industry median Equity-to-Asset is 0.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Healthcare Providers & Services company?
The median Equity-to-Asset among Healthcare Providers & Services companies is 0.48, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cryo-Cell International and its competitors. For the Healthcare Providers & Services industry, the median Equity-to-Asset is 0.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryo-Cell International's current Equity-to-Asset is -0.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryo-Cell International stock overvalued right now?
Based on GuruFocus' analysis, Cryo-Cell International (CCEL) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.43, compared to a current price of $4.39 — trading 19.2% below its estimated fair value. The current Equity-to-Asset is -0.29. Cryo-Cell International's overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Cryo-Cell International (CCEL), the current Equity-to-Asset is -0.29 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryo-Cell International (CCEL) Overvalued in 2026?
Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued.
The current stock price of $4.39 is trading 19.2% below its estimated GF Value™ of $5.43.
GuruFocus considers Cryo-Cell International to be Modestly Undervalued.
Key valuation signals for CCEL:
Equity-to-Asset: -0.29
GF Value™: $5.43 vs. price of $4.39 (19.2% below fair value)
No single metric tells the full story. See the CCEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
61GF Score
Get the complete analysis for CCEL
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CCEL has been successfully added to your 
